📰 Early Mortality News
Early Mortality News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Early Mortality. Real-time updates on events, politics, business and more.
February 20, 2024
Calysta’s FeedKind has received formal approval for use in aquafeeds in China as the company’s joint venture prepares to deliver first product to customers
August 16, 2023
Breakthrough treatment reduces new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, fibrodysplasia...
August 16, 2023
Breakthrough treatment reduces new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, fibrodysplasia ossificans progressiva FOP impacts about 400... -Today at 03:33 pm- MarketScreener
August 11, 2023
A posthoc analysis of the pivotal SOLOIST-WHF trial provides insight into the effects of sotagliflozin use on risk of cardiovascular mortality and heart failure readmissions at 90 days.
July 27, 2023
Ultra-Processed Diets: A recent study involving more than 1,000 people with type 2 diabetes in Italy has raised concerns.
June 2, 2023
Fourteen presenters from six countries were recognized for excellence for their presentations on machine learning, non-invasive therapy techniques,...
October 28, 2022
This study examines the impact of the trauma team leader (TTL) on 72-hour mortality and admission delays from the emergency department. Learn more!
May 12, 2021
Bristol Myers Squibb Presents New Research at ASCO and EHA 2021 Featuring Novel Approaches and Demonstrating Significant Progress to Improve Survival in Cancer and Blood Disorders First Phase 3 data from the RELATIVITY-047 trial highlight clinical benefit of LAG-3 blocking antibody relatlimab the company’s third distinct checkpoint inhibitor in combination with nivolumab for patients with previously untreated unresectable or metastatic melanoma First disclosure of results from CheckMate -648 ...
April 23, 2021
If approved, Onureg will become the first and only once daily oral frontline maintenance therapy in Europe for patients with a broad range of acute myeloid leukemia subtypes In the pivotal QUAZAR ® AML-001 study, Onureg demonstrated significant overall survival and showed a relapse-free survival benefit in patients with AML in first remission Bristol Myers Squibb today announced the Committee for Medicinal Products … If approved, Onureg will become the first and only once daily oral frontli...